251. Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma
- Author
-
Toru Akiyama, Kenji Sato, Sakae Tanaka, Toshihide Hirai, Hirotaka Kawano, Yusuke Shinoda, Takahiro Goto, Tomotake Okuma, Hiroshi Kobayashi, Ryoko Sawada, Takahiro Ohki, Hiroyuki Oka, Satoshi Abe, and Masachika Ikegami
- Subjects
0301 basic medicine ,Oncology ,Male ,Pathology ,Neutrophils ,medicine.medical_treatment ,Cell Count ,0302 clinical medicine ,Surgical oncology ,Lymphocytes ,Aged, 80 and over ,Sulfonamides ,Soft tissue sarcoma ,Hazard ratio ,Sarcoma ,Hematology ,General Medicine ,Middle Aged ,Prognosis ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,medicine.drug ,Adult ,Blood Platelets ,medicine.medical_specialty ,Indazoles ,Adolescent ,Disease-Free Survival ,Pazopanib ,03 medical and health sciences ,Young Adult ,Internal medicine ,medicine ,Biomarkers, Tumor ,Humans ,Neutrophil to lymphocyte ratio ,Aged ,Proportional Hazards Models ,Chemotherapy ,business.industry ,fungi ,medicine.disease ,Clinical trial ,030104 developmental biology ,Pyrimidines ,Surgery ,business - Abstract
Pazopanib is a multi-tyrosine kinase inhibitor that is used to treat advanced soft-tissue sarcoma, and its efficacy has been confirmed in several clinical trials, although no clinically useful biomarkers have been identified. In other cancers, the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and the lymphocyte-to-monocyte ratio (LMR) are associated with chemotherapy response and prognosis. Therefore, we aimed to evaluate the associations of pazopanib response with NLR, PLR, and LMR among patients with advanced soft-tissue sarcoma. Data regarding NLR, PLR, and LMR were obtained for 25 patients who received pazopanib for soft-tissue sarcoma. The patients were categorized according to their values for NLR (≥3.8 vs.
- Published
- 2017